<unk>  is indicated in combination with other antiretroviral agents for the treatment of HIV-1-infected patients. In December 2021, the combination of nirmatrelvir and<unk>  was granted emergency use authorization by the US Food and Drug Administration (FDA) for the treatment of coronavirus disease COVID-19. The co-packaged medications are sold under the brand name Paxlovid. Paxlovid is not authorized for the pre-exposure or post-exposure prevention of COVID-19 or for initiation of treatment in those requiring hospitalization due to severe or critical COVID-19. On 31 December 2021, the UK Medicines and Healthcare products Regulatory Agency (MHRA) approved the same combination "for people with mild to moderate COVID-19 who are at high risk of developing severe COVID-19".
Ritonavir
Amprenavir
Saquinavir
Fosamprenavir
Indinavir
Nelfinavir
Atazanavir
Entecavir